NDAORALTABLET
Approved
Nov 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
ALVAIZ (eltrombopag) by Teva is tpo-receptor agonist that interacts with the transmembrane domain of the human tpo-receptor (also known as cmpl) and initiates signaling cascades that induce proliferation and differentiation of megakaryocytes leading to increased platelet production. First approved in 2023.
Drug data last refreshed 9h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALVAIZ (eltrombopag) is an oral TPO-receptor agonist approved by the FDA in November 2023 that works by binding to the transmembrane domain of the thrombopoietin receptor to stimulate megakaryocyte proliferation and differentiation, thereby increasing platelet production. It is indicated for patients with thrombocytopenia who require platelet count elevation. The drug represents Teva's entry into the platelet disorders market with a small-molecule mechanism targeting unmet needs in immune thrombocytopenia and related conditions.
Growth12.1 years to LOE
Early-stage product in growth phase with no current competitive pressure; commercial teams are building market infrastructure and expanding prescriber adoption.
Mechanism of Action
TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor (also known as cMpl) and initiates signaling cascades that induce proliferation and differentiation of megakaryocytes leading to increased platelet production.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.
Started Feb 2027
36 enrolled
Primary Immune Thrombocytopenia (ITP)
A Real-world Study of Treatment Patterns and Outcomes in Primary Immune Thrombocytopenia Patients Treated With Eltrombopag
Started Jun 2026
150 enrolled
Immune Thrombocytopenia
Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP
Started Dec 2025
150 enrolled
Primary Immune Thrombocytopenia (ITP)
Study on the Short-term Efficacy and Safety of Recombinant Human Thrombopoietin Combined With Immunosuppressant Sequential Eltrombopag Ethanolamine Dry Suspension in the Treatment of SAA/TD-NSAA
Started Jun 2025
70 enrolled
Aplastic Anemias
Bioequivalence Study of Revolade® Eltrombopag 50 mg
Started Jun 2025
30 enrolled
HealthyHealthy Donors
Worked on ALVAIZ at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.